New Study Confirms 487-GEP for Choosing JAK Inhibitors in Severe AD
Clinical Validation of a Novel Gene Expression Test for Atopic Dermatitis
A recently published prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology (JAAD) has explored the clinical efficacy of a gene expression profile test aimed at guiding the choice of systemic treatments for patients with moderate to severe atopic dermatitis (AD).
The study focused on Castle Biosciences’ AdvanceAD-Tx, a noninvasive diagnostic tool designed to provide objective molecular insights at the point of care for individuals aged 12 years and older who are considering systemic therapies. This innovative test analyzes lesional skin scrapings without the need for invasive biopsies, measuring the expression of 487 genes involved in 12 key inflammatory and cutaneous biology pathways.
Study Design and Patient Stratification
The research utilized RNA sequencing data from 192 patients to develop the testing algorithm, followed by validation with an independent cohort of 110 AD patients aged 12 years and older. The test successfully classified patients into two distinct molecular profiles: the JAK inhibitor (JAKi) Responder Profile (30.4%) and the Th2 Molecular Profile (69.6%).
These molecular profiles allowed for the stratification of patients based on their likelihood of responding to JAKi therapy versus Th2-targeted treatments, which are the two primary classes of systemic therapies available for AD. Dr. Aaron Farberg, a double board-certified dermatologist and Mohs surgeon, emphasized the significance of this development, stating, “For years, systemic treatment decisions in AD have relied on clinical assessment and experience.”
He further noted that the disease’s heterogeneity and biological complexity necessitate a more objective method to identify the most active immune pathways in each patient, enhancing the selection of effective therapies.
Insights into Treatment Outcomes
The study’s findings present prospective data advocating for a precision medicine approach in managing AD, which could have substantial implications for improving response rates, accelerating time to clearance, and enhancing patient-reported outcomes in everyday clinical practice.
Clinically, patients identified with the JAKi Responder Profile who underwent JAKi therapy exhibited significantly better outcomes compared to those receiving Th2-targeted therapies. Specifically, 45.5% of these patients achieved EASI 90 within three months, in contrast to only 8.3% of patients on Th2-targeted therapies (p=0.021).
Moreover, those on the JAKi treatment reached EASI 90 approximately 3.8 times faster (p=0.049) and experienced higher rates of complete lesion clearance (vIGA-AD 0), lack of itch, and increased flare-free survival. In contrast, patients with a Th2 Molecular Profile did not show significant differences in clinical responses between the treatment classes, indicating the broad immunomodulatory effects of JAKi on Th2-driven disease without a definitive superiority over Th2 biologics in this subgroup.
Implications of Molecular Profiling
The publication in JAAD underscores the potential of molecular profiling in tailoring systemic therapies for AD. The 487-gene expression profile empowers clinicians to pinpoint patients who are likely to be “super-responders” to JAKi, facilitating more targeted treatment decisions that could minimize ineffective therapy trials and ultimately improve the quality of life for patients.
An essential aspect of this test is its non-invasive sampling method, which leverages familiar scraping techniques for clinical implementation, eliminating the need for cumbersome procedures. Dr. Mark G. Lebwohl, the senior study author and a leading figure in dermatology, commented, “Atopic dermatitis can look similar on the surface, but the biology driving the disease can differ meaningfully from patient to patient.”
He further stated, “This study shows that AdvanceAD-Tx can provide objective molecular insight to help clinicians better align systemic therapy choices with an individual patient’s disease biology earlier in the treatment journey and improve outcomes that matter to patients.”
Limitations and Future Directions
While the findings are promising, it is important to note certain limitations, such as the validation being restricted to patients aged 12 years and older, as well as the rapid evolution of emerging AD therapies that are not yet included in the test.
Nonetheless, this approach signifies a major step forward in the realm of precision dermatology. The adoption of the 487-GEP test could offer a solid framework for personalized systemic treatment, enhancing efficacy while potentially alleviating the treatment burden associated with moderate to severe AD.
Dr. Farberg concluded, “Now we have the potential to move beyond the old system of picking and adjusting therapies by identifying the underlying immune pathways that drive AD to guide treatment more precisely. For our patients, it means faster relief and fewer setbacks. For dermatologists, it means greater confidence in knowing we are treating not only what we see on the surface but also the biology beneath it. That’s the promise of molecular insight, and it marks an exciting new era for care in AD.”
Sources
- Castle Biosciences press release, Prospective Validation Study in JAAD.
- Silverberg JI, Eichenfield LF, Armstrong AW, et al., The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: results from a prospective trial.
- Farberg A., Precision medicine arrives in atopic dermatitis: guiding systemic treatment decisions through gene expression profiling.